Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 2/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 1.00 |
| ▸ | PDE4A | P27815 | 1/20 | 0.75 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.75 |
| ▸ | BLM | P54132 | 2/20 | 0.49 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.49 |
| ▸ | GSR | P00390 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.44 |
| ▸ | CA12 | O43570 | 1/20 | 0.40 |
| ▸ | CA9 | Q16790 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | RECQL | P46063 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Semustine SCHEMBL4959160 | 1.00 | ALDH1A1 (1.00) | ALDH1A1ADRA2ASMN1; SMN2PDE4AADRA1A | |
| Semustine SCHEMBL28854924 | 0.98 | ALDH1A1 (0.97) | ALDH1A1ADRA2ASMN1; SMN2PDE4AADRA1A | |
| Semustine SCHEMBL2350016 | 0.96 | ALDH1A1 (0.92) | ALDH1A1ADRA2ASMN1; SMN2PDE4AADRA1A | |
| Semustine SCHEMBL8980108 | 0.89 | ALDH1A1 (0.79) | ALDH1A1ADRA2ASMN1; SMN2PDE4AADRA1A | |
| SCHEMBL3341311 | 0.86 | ADRA2A (0.77) | ALDH1A1ADRA2ASMN1; SMN2PDE4AADRA1A | |
| SCHEMBL3341308 | 0.86 | ADRA2A (0.77) | ALDH1A1ADRA2ASMN1; SMN2PDE4AADRA1A | |
| Lomustine SCHEMBL868328 | 0.86 | ADRA2A (1.00) | ALDH1A1ADRA2ASMN1; SMN2PDE4AADRA1A | |
| Lomustine SCHEMBL3995 | 0.86 | ADRA2A (1.00) | ALDH1A1ADRA2ASMN1; SMN2PDE4AADRA1A | |
| SCHEMBL21693655 | 0.85 | ADRA2A (0.75) | ALDH1A1ADRA2ASMN1; SMN2PDE4AADRA1A | |
| SCHEMBL21693656 | 0.85 | ADRA2A (0.75) | ALDH1A1ADRA2ASMN1; SMN2PDE4AADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 37090 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3978473-B1 | COMPOUND CONTAINING AN INDOLEACETIC ACID CORE STRUCTURE AND USE THEREOF | BEIJING AN JIAN XI BIO MEDICAL TECH CO LTD (CN) | 2026-05-06 | — | — | EP | claimed |
| US-20260116861-A1 | ISOXAZOLE HYDROXAMIC ACIDS AS HISTONE DEACETYLASE 6 INHIBITORS | THE GEORGE WASHINGTON UNIVERSITY, A CONGRESSIONALLY CHARTERED NOT-FOR-PROFIT CORPORATION (US) | 2026-04-30 | — | — | US | claimed |
| EP-4729063-A2 | TREATMENT OF CANCER USING COENZYME Q10 COMBINATION THERAPIES | BPGbio, Inc. (US) | 2026-04-22 | — | — | EP | claimed |
| US-20260102468-A1 | COMPOSITIONS AND METHODS FOR MARCO INHIBITION AND IMPROVED DRUG DELIVERY | UNIV TEXAS (US) | 2026-04-16 | — | — | US | claimed |
| EP-3515892-B1 | COMPOUNDS AND METHODS FOR IDO AND TDO MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC (US) | 2026-04-15 | — | — | EP | claimed |
| EP-4719455-A2 | METHODS FOR TREATING IGF-1R-RELATED PEDIATRIC CANCERS WITH AN INSULIN-LIKE GROWTH FACTOR 1 RECEPTOR LIGAND CONJUGATED TO A CYTOTOXIC AGENT | Lirum Therapeutics, Inc. (US) | 2026-04-08 | — | — | EP | claimed |
| EP-4719451-A2 | METHODS FOR TREATING IGF-1R-RELATED CANCERS WITH AN INSULIN-LIKE GROWTH FACTOR 1 RECEPTOR LIGAND CONJUGATED TO A CYTOTOXIC AGENT | Lirum Therapeutics, Inc. (US) | 2026-04-08 | — | — | EP | claimed |
| US-20260085061-A1 | PHTHALAZINE DERIVATIVES AS PYRUVATE KINASE MODULATORS | SITRYX THERAPEUTICS LIMITED (GB) | 2026-03-26 | — | — | US | claimed |
| EP-4710918-A1 | OPHTHALMIC PHARMACEUTICAL COMPOSITION AND PREPARATION METHOD THEREFOR, OPHTHALMIC KIT CONTAINING OPHTHALMIC PHARMACEUTICAL COMPOSITION, AND USE | Shenyang Xingqi Pharmaceutical Co., Ltd. (CN) | 2026-03-18 | — | — | EP | claimed |
| CN-121586579-A | Methods for treating IGF-1R-related cancers with insulin-like growth factor 1 receptor ligands conjugated to cytotoxic agents | 利鲁姆治疗公司 | 2026-02-27 | — | — | CN | claimed |
| EP-0546951-A1 | Combination of liposome encapsulated antineoplastic agents, such as doxorubicin with colony stimulating factors | THE LIPOSOME COMPANY, INC. (US) | 1993-06-16 | — | — | EP | claimed |
| EP-0359347-B1 | COVALENTLY-LINKED COMPLEXES AND METHODS FOR ENHANCED CYTOTOXICITY AND IMAGING | NEORX CORPORATION (US) | 1992-12-23 | — | — | EP | claimed |
| EP-0478631-A1 | TARGETTING AGENTS. | CANCER RES CAMPAIGN TECH (GB) | 1992-04-08 | — | — | EP | claimed |
| US-5024998-A | Administering in aqueous solution with cyclodextrin derivative | UNIVERSITY OF FLORIDA (US) | 1991-06-18 | — | — | US | claimed |
| WO-1991000111-A1 | TARGETTING AGENTS | CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED (GB) | 1991-01-10 | — | — | WO | claimed |
| US-4983586-A | Decreasing precipitation at injection site or in lungs or other organs by combining with hydroxypropyl-beta-cyclodextrin | UNIVERSITY OF FLORIDA (US) | 1991-01-08 | — | — | US | claimed |
| EP-0393575-A1 | Neoplasia treatment compositions containing antineoplastic agent and side-effect reducing protective agent | G.D. Searle & Co. (US) | 1990-10-24 | — | — | EP | claimed |
| EP-0359347-A2 | Covalently-linked complexes and methods for enhanced cytotoxicity and imaging | NEORX CORPORATION (US) | 1990-03-21 | — | — | EP | claimed |
| EP-0335545-A2 | Pharmaceutical formulations for parenteral use | UNIVERSITY OF FLORIDA (US) | 1989-10-04 | — | — | EP | claimed |
| EP-0227593-A1 | Use of chelating agents | THE HOSPITAL FOR SICK CHILDREN (CA) | 1987-07-01 | — | — | EP | claimed |